Abstract:Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC There have been a lot studies focusing on EGFR mutation analysis in the patients of lung cancer especially in the patients with adenocarcinoma, for EGFR mutation has shown helpful in patient prognosis and therapeutic selection. Erlotinib and Gefitinib are playing increasing role in late stage adenocarcinoma of lung although it has not been listed as a first line treatment for advanced patients of Asian ethnic yet. However, the fact of a better respond rate to Erlotinib and Gefitinib and longer survival related to the mutant status of EGFR gene among Asian patients is encouraging the use for routine test of this gene in clinical service for lung cancer patients. Ninety two Chinese cancer patients were included into the study, from which 60 were lung cancer. The other cases were 11 supraclavicular lymph node biopsies and 21 tumor masses of different sites with differentiation diagnosis needed. EGFR mutation analysis was performed in DNA extracted from tumor tissue or biopsy samples. Overall mutation rate of EGFR was 42.39% (39/92) in whole patient group. The mutation rate in lung cancer was 46.67% (28/60) whereas it turned to 58.14% (25/43) when only looking at adenocarcinoma (56.10%, 23/41) and adenosquamous carcinoma (100%, 2/2). No mutation was found in squamous carcinoma, large cell carcinoma and poorly differentiated carcinoma. EGFR mutation analysis in the samples from Endobronchila Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) for mediastinal masses revealed an EGFR mutation rate of 42.86% (3/7), mimicking the mutation rate of lung cancer in our study. Forty eight percent of the EGFR mutation was located in exon 19 and 36% of the mutation in exon 21. Mutation of exon 19 seemed to be lower in the patient group older (35.71%, 5/14) than 58 year old (median age) than that in the patient group younger than 58 year old (58.82%, 10/17) (P=0.0581). In opposition, mutation rate of exon 21 appeared higher in the older group (64.29%, 9/14) than that in the younger patient group (23.53%, 4/17) (P=0.0800). The mutations in male patients were mainly located in exon 19 (71.43%, 10/14). And the mutation rate of exon 19 and 21 in female patients showed very close (43.47%, 10/23 for exon 19 and 47.83%, 11/23 for exon 21). Mutation rate of exon 20 was generally low but showed a higher rate in younger and female patients (17.65% and 13.04%). Mutation of supraclavicular lymph node was quite high (36.37%, 4/11) while mutation rate from variant site was low (20.00%, 4/20). One adenocarcinoma located in uterus muscle layer was demonstrated to possess an exon 19 mutation. All follow up analysis is in process. In conclusion, EGFR mutation analysis is a useful tool in defining patients suitable for EGFR TKI treatment as well as helpful in differentiation diagnosis in metastasis lesion. Mutation analysis in the samples derived from EBUS-TBNA is especially of important with clinical value. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4669.

Are Exon 19 Deletions and L858R Different in Early Stage Lung Adenocarcinoma?

Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement

Clinical Outcomes of EGFR-TKI Treatment and Genetic Heterogeneity in Lung Adenocarcinoma Patients with EGFR Mutations on Exons 19 and 21

EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis.

A Novel Acquired EGFR-SEPT14 Fusion Confers Differential Drug Resistance to EGFR Inhibitors in Lung Adenocarcinoma.

Exploring the Cause of Survival Disparities in EGFR-mutated Lung Cancer Subtypes: Unraveling Distinctive Genomic and Phenotypic Features of 19del and L858R Mutation Subtypes

Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study

An exon 19 mutation of EGFR gene in the serum circulating DNA from patients with advanced lung cancer

Mutational analysis of exons 19 and 21 of the EGFR gene in lung adenocarcinoma

Better Survival with Epidermal Growth Factor Receptor Exon 19 Deletion Than with Exon 21 Mutation in Gefitinib-Treated Non-Small Cell Lung Cancer Patients is Due to Differential Inhibition of Downstream Signals

Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations

Prevalence, Clinicopathologic Characteristics, and Molecular Associations of EGFR Exon 20 Insertion Mutations in East Asian Patients with Lung Adenocarcinoma

The Comparison of Egfr-Tki Failure Modes and Subsequent Management Between Exon 19 Deletion and Exon 21 L858r Mutation in Advanced Non-Small-Cell Lung Cancer

EGFR Gene Mutation and Methodological Evaluation in 399 Patients with Non-small Cell Lung Cancer

Abstract 4669: EGFR Gene Mutation Analysis in Chinese Lung Cancer Patients: Value for Differentiation Diagnostics and Therapeutics

The prognostic impact of epidermal growth factor receptor mutation in clinical stage I lung adenocarcinoma

Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naïve advanced lung adenocarcinoma.

Epidermal growth factor receptor mutations in Chinese patients with adenocarcinoma of the lung

EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors

Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study

Abstract 5774: Are 19del and L858R really not the same disease entities